Hemophilia and Thrombosis Center "A. Bianchi Bonomi," IRCCS Cà Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy.
Semin Thromb Hemost. 2013 Oct;39(7):697-701. doi: 10.1055/s-0033-1353996. Epub 2013 Sep 8.
Hemophilia A and B are traditionally considered clinically indistinguishable; however, differences in bleeding frequency, clinical scores, use of prophylaxis, and need for orthopedic surgery have been reported, suggesting that the bleeding tendency associated with factor IX deficiency may be less severe with consequent better outcomes in the long term.Hemophilia A and B show their own peculiar aspects, not only in terms of epidemiological and clinical features, including inhibitor incidence and associated symptoms, but also with respect to molecular defects. The type of factor VIII/IX mutation is a major determinant of the bleeding tendency as well as of the risk of inhibitor formation; thus, there is a biological plausibility behind the different clinical expression of these two forms of congenital hemophilia. The distinction of various bleeding phenotypes in hemophilia has considerable therapeutic implications; therefore, further research in this field is required to optimize treatment regimens.
血友病 A 和 B 传统上被认为在临床上难以区分;然而,已经报道了出血频率、临床评分、预防治疗的使用和骨科手术的需求存在差异,这表明与因子 IX 缺乏相关的出血倾向可能较轻,因此长期预后较好。血友病 A 和 B 在流行病学和临床特征方面,包括抑制剂的发生率和相关症状,以及分子缺陷方面,都表现出其自身的特点。因子 VIII/IX 突变的类型是出血倾向以及抑制剂形成风险的主要决定因素;因此,这两种先天性血友病在临床表现上的不同具有一定的生物学合理性。血友病中各种出血表型的区分具有重要的治疗意义;因此,需要进一步研究这一领域,以优化治疗方案。